Which of the following options does NOT describe what interim analysis can lead to?

Question

BlackTom AI · Accepted Answer

Interim analyses are planned evaluations of accumulating trial data performed before formal study completion; they are used within adaptive designs to make prespecified, statistically controlled changes while preserving validity (Type I error control) and patient safety.

1) Relevant knowledge points and concepts
- Interim (or interim) analysis: pre-specified looks at data during a trial, often conducted by independent data monitoring committees.  
- Adaptive trial changes that are commonly allowed: sample size re-estimation, dose adjustments (especially in dose-finding or seamless phase 2/3 designs), stopping early for efficacy or futility, and enrichment or modification of inclusion criteria.  
- Endpoint definition: the primary clinical endpoint is a core protocol element and should be fixed a priori; changing it after looking at interim results risks bias and invalidates statistical inference.

2) Step-by-step reasoning
- Does interim analysis allow dosage modifications? Yes: adaptive dosing and dose-escalation decisions (e.g., Bayesian adaptive dose-finding) are classic uses of interim data.  
- Does it allow changes to the number of patients? Yes: sample size re-estimation based on observed event rates or variance is a well-established interim procedure.  
- Does it allow changes in patient selection criteria? Yes: adaptive enrichment designs use interim information to restrict or expand enrollment to subgroups showing benefit.  
- Does it allow changes in the clinical endpoint? No: the primary endpoint is part of the study hypothesis and statistical plan; changing it after seeing data would introduce bias and typically violates regulatory and methodological standards.

3) Calculations
- No numerical calculations apply here; decisions are conceptual and governed by protocol and statistical control procedures.

4) Why the correct answer is correct
- Option c (Changes in the clinical endpoint) is not something interim analyses should lead to because it undermines trial integrity and Type I error control; therefore it is the correct “NOT” choice.

5) Why other options are incorrect
- a, b, and d describe legitimate, prespecified adaptive actions (dose modification, sample size changes, enrichment) that interim analyses can support under proper control.

Conclusion: The correct answer is c. Changes in the clinical endpoint do NOT describe what interim analysis can lead to.

Which of the following options does NOT describe what interim analysis can lead to?Single choice

Similar Questions

Which of the following best describes an adaptive trial design?

Which of the following options is NOT a purpose of conducting Phase IV clinical trials?

Is the following statement true or false? In the products of methylation-hydrolysis, every -OH group corresponds to the position of a glycosidic bond in the starting polysaccharide.

Which of the follwoing structures represents amylopectin?

Which of the following is true about an aldopentose?I. It is a monosaccharide.II. It contains a CHO groupIII. It is a disaccharide.IV. It is an oligosaccharide.

For stock A, we have 𝛽 𝑖 = 0.70. Suppose the expected market risk premium next year is 9% and the risk-free rate is 3%. What is the expected return of this stock based on the CAPM? (Please answer in % and round to 2 decimal places. If the answer is 8.057%, then in the box, write 8.06)

More Practical Tools for Students Powered by AI Study Helper

Homework AI Solver

Stylized AI Paper Writer

Plagiarism Checker Assistant

Citation AI Academic Writing Tool

In-Class Translation Assistant

AI Note Generator

AI Quiz Answers

Past Exam Questions from University Test Bank

Smart Practice Assistant

Adaptive Practice

Making Your Study Simpler